The company said it expects the deal to be formally signed during its the 1st quarter of fiscal year 2016/2017, with the bulk of installations scheduled for April 2017.
“As a Swedish corporation headquartered in Stockholm, and as a world leader in cancer care, we are delighted to be awarded this prestigious tender. We are fully committed to investing in research and innovation and in providing our state-of-the-art technology in collaboration with NKS, in order to strengthen cancer care in the Stockholm region. It is exciting to further expand and deepen our collaboration with Karolinska, the hospital where stereotactic radiotherapy originated. Karolinska is a visionary and a great partner to Elekta’s own pioneering spirit in research, development and clinical advancement to support cancer care throughout the world,” Elekta CEO Tomas Puusepp said in a prepared statement.
The final supply decision is pending a 10-day review process during which the decision can be appealed, Stockholm-based Elekta said.
Last month, Elekta said it inked an 8-year strategic partnership with Australian radiotherapy provider GenesisCare for more than $100m.
The new partnership includes the acquisition of Elekta’s Leksell Gamma Knife Icon radiosurgery systems, Versa HD linear accelerators, brachytherapy systems, software and other services, Elekta said.
GenesisCare will use the acquired products and solutions for its cancer treatment centers in Australia, the UK and “new markets,” the company said.